HFE C282Y heterozygosity in hepatocellular carcinoma: Evidence for an increased prevalence

Clinical Gastroenterology and Hepatology

Volumn 1, Issue 4, 2003, Pages 279-284

  Hellerbrand, Claus ^a   Pöppl, Andreas ^a   Hartmann, Arndt ^a   Schölmerich, Jürgen ^a   Lock, Guntram ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON; TRANSFERRIN;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HEMOCHROMATOSIS; HETEROZYGOSITY; HFE GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IRON OVERLOAD; IRON STORAGE; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; RISK FACTOR; WILD TYPE;

EID: 0141920693     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(03)00132-0     Document Type: Article

References (35)

1. Weinberg ED. The role of iron in cancer. Eur J Cancer Prev 1996;5:19-36.
2. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353:1253-1257.
3. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256-1262.
4. Zhou XD, DeTolla L, Custer RP, London WT. Iron, ferritin, hepatitis B surface and core antigens in the livers of Chinese patients with hepatocellular carcinoma. Cancer 1987;59:1430-1437.
5. Turlin B, Juguet F, Moirand R, Le Quilleuc D, Loreal O, Campion JP, Launois B, Ramee MP, Brissot P, Deugnier Y. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 1995;22:446-450.
6. Mandishona E, MacPhail AP, Gordeuk VR, Kedda MA, Paterson AC, Rouault TA, Kew MC. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 1998;27:1563-1566.
7. Deugnier Y, Turlin B, Loreal O. Iron and neoplasia. J Hepatol 1998;28(suppl 1):21-25.
8. Knoll A, Kreuzpaintner B, Kreuzpaintner E, Jilg W, Lock G, Hartmann A. Hemochromatosis mutation in hepatitis C: histopathology. Gastroenterology 1998;115:1307-1309.
9. Chapoutot C, Esslimani M, Joomaye Z, Ramos J, Perney P, Laurent C, Fabbro-Peray P, Larrey D, Domergue J, Blanc F. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut 2000;46:711-714.
10. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class 1-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996;13:399-409.
11. Beutler E. The significance of the 187G (H63D) mutation in hemochromatosis. Am J Hum Genet 1997;61:762-764.
12. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N, Tsuchihashi Z, Sigal E, Bjorkman PJ, Schatzman RC. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A 1998;95:1472-1477.
13. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986;6:24-29.
14. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996;335:1799-1805.
15. Merryweather-Clarke AT, Worwood M, Parkinson L, Mattock C, Pointon JJ, Shearman JD, Robson KJ. The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. Br J Haematol 1998;101:369-373.
16. Burt MJ, George PM, Upton JD, Collett JA, Frampton CM, Chapman TM, Walmsley TA, Chapman BA. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut 1998;43:830-836.
17. Ishak KG. Histological typing of tumors of the liver. Berlin, Springer Verlag, 1994.
18. Scheuer PJ, Williams R, Muir AR. Hepatic pathology in relatives of patients with hemochromatosis. J Pathol Bacteriol 1962;84:53-64.
19. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
20. Jeffrey GP, Chakrabarti S, Hegele RA, Adams PC. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nat Genet 1999;22:325-326.
21. Aldersley MA, Howdle PD, Wyatt JI, Robinson PA, Markham AF. Haemochromatosis gene mutation in liver disease patients. Lancet 1997;349:1025-1026.
22. Hezode C, Cazeneuve C, Coue O, Roudot-Thoraval F, Lonjon I, Bastie A, Duvoux C, Pawlotsky JM, Zafrani ES, Amselem S, Dhumeaux D. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999;31:979-984.
23. George DK, Powell LW, Losowsky MS. The haemochromatosis gene: a co-factor for chronic liver diseases? J Gastroenterol Hepatol 1999;14:745-749.
24. Blanc JF, De Ledinghen V, Bernard PH, de Verneuil H, Winnock M, Le Bail B, Carles J, Saric J, Balabaud C, Bioulac-Sage P. Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol 2000;32:805-811.
25. Beckman LE, Van Landeghem GF, Sikstrom C, Wahlin A, Markevarn B, Hallmans G, Lenner P, Athlin L, Stenling R, Beckman L. Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis 1999;20:1231-1233.
26. Willis G, Wimperis JZ, Lonsdale R, Fellows IW, Watson MA, Skipper LM, Jennings BA. Incidence of liver disease in people with HFE mutations. Gut 2000;46:401-404.
27. Bralet MP, Degott C, Belghiti J, Terris B. Prevalence of the haemochromatosis gene mutation in non-cirrhotic liver with hepatocellular carcinoma. J Hepatol 1998;28:740.
28. Pirisi M, Toniutto P, Uzzau A, Fabris C, Avellini C, Scott C, Apollonio L, Beltrami CA, Bresadola F. Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients. Cancer 2000;89:297-302.
29. Racchi O, Mangerini R, Rapezzi D, Gaetani GF, Nobile MT, Picciotto A, Ferraris AM. Mutations of the HFE gene and the risk of hepatocellular carcinoma. Blood Cells Mol Dis 1999;25:350-353.
30. Gottschalk R, Seidl C, Loffler T, Seifried E, Hoelzer D, Kaltwasser JP. HFE codon 63/282 (H63D/C282Y) dimorphism in German patients with genetic hemochromatosis. Tissue Antigens 1998;51:270-275.
31. Hohler T, Leininger S, Kohler HH, Schirmacher P, Galle PR. Heterozygosity for the hemochromatosis gene in liver diseases-prevalence and effects on liver histology. Liver 2000;20:482-486.
32. Britton RS. Metal-induced hepatotoxicity. Semin Liver Dis 1996;16:3-12.
33. Poulsen HE, Jensen BR, Weimann A, Jensen SA, Sorensen M, Loft S. Antioxidants, DNA damage and gene expression. Free Radic Res 2000;33(suppl):S33-S39.
34. Terada T, Nakanuma Y. Survey of iron-accumulative macroregenerative nodules in cirrhotic livers. Hepatology 1989;10:851-854.
35. Furuya K, Nakamura M, Yamamoto Y, Togei K, Otsuka H. Macroregenerative nodule of the liver. A clinicopathologic study of 345 autopsy cases of chronic liver disease. Cancer 1988;61:99-105.